|
Mr. Rakin, a founder and a member of the company’s Board of Directors, was appointed President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc. (NASDAQ: GNSC) in August 2002. Mr. Rakin previously served as the company’s President and Chief Financial Officer. As Chief Financial Officer, he was responsible for Finance and Operations and completed private and public financings which totaled in excess of $150 million. Mr. Rakin was previously a Principal at The Stevenson Group, where he provided investment, strategic and merchant banking services to high-growth technology companies and venture capital firms. He has thirteen years of experience in the genomics sector, having previously founded BIOS Laboratories and served as the acting CFO of Gene Logic, Inc. From 1982 to 1990, he was associated with Ernst and Young and served as a Manager in the Entrepreneurial Services Group. Mr. Rakin is co-Chairman of the Board of Directors of Connecticut United For Research Excellence (CURE), Connecticut’s Bioscience Cluster. He is also on the Board of Directors of the MIT Enterprise Forum ® of Connecticut, Inc., an organization that services and supports the entrepreneurial business community. Mr. Rakin received a BS in Business and an MS in Finance from the University of Cape Town and an MBA from Columbia University. Mr. Zuga developed a relationship with Mr. Rakin in 1999, when Legg Mason was engaged to provide investment banking services to Genaissance. Since that time, Mr. Zuga advised the company on various transactions, including a Series B and Series C Preferred Stock financing that totaled in excess of $60 million. Mr. Klein is a member of the company’s Board of Directors. Return to CEO’s Council | 